Results 161 to 170 of about 127,263 (196)
Some of the next articles are maybe not open access.
Glucagon-like Peptide-1 and Islet Lipolysis
Hormone and Metabolic Research, 2004A role for glucagon-like peptide 1 (GLP-1) has been suggested in stimulating beta-cell lipolysis via elevation of cAMP and activation of protein kinase A, which in turn may activate hormone-sensitive lipase (HSL), thereby contributing to fatty acid generation (FFA) from intracellular triglyceride stores.
M, Sörhede Winzell, B, Ahrén
openaire +2 more sources
Glucagon-Like Peptide 1—A Cardiologic Dimension
Trends in Cardiovascular Medicine, 2010Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant.
Treiman, Marek +3 more
openaire +3 more sources
The discovery of glucagon-like peptide 1
Regulatory Peptides, 2005The discovery of glucagon-like peptide 1 (GLP-1) began more than two decades ago with the observations that anglerfish islet proglucagon messenger RNAs (mRNAs) contained coding sequences for two glucagon-related peptides arranged in tandem. Subsequent analyses revealed that mammalian proglucagon mRNAs encoded a precursor containing the sequence of ...
openaire +2 more sources
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Endocrine Reviews, 2023Daniel J Drucker
exaly
[Glucagon-like peptide 1 (GLP-1)].
MMW Fortschritte der Medizin, 2007GLP-1 receptor agonists such as exenatide are a group of new therapeutic agents that mimic the gut-derived incretin hormone GLP-1. These drugs stimulate insulin secretion while suppressing glucagon secretion, inhibit gastric motility, reduce appetite and hence, food intake.
openaire +1 more source
[Glucagon-like peptide-1(GLP-1)].
Nihon rinsho. Japanese journal of clinical medicine, 2004Glucagon-like peptide-1(GLP-1), an intestinal hormone secreted by L cells in response to luminal nutrients(carbohydrate and fat), enhances glucose-induced insulin secretion. Impairment of glucose-induced insulin secretion in patients with type 2 diabetes can be restored to near-normal by GLP-1 administration.
openaire +1 more source